Clinical trials: Lung Cancer Non-small Cell Stage IV
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Cancer
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating…
- Trial name
- NCT00017459
- Testing
- cisplatin, tirapazamine, vinorelbine tartrate
- Where
- 42 sites in United States
- Sponsor
- Sanofi
Lung Cancer
Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227708
- Testing
- docetaxel, quality-of-life assessment
- Where
- 9 sites in France, Switzerland and 1 more
- Volunteers
- 58 people
- Sponsor
- UNICANCER
Carcinoma, Non-Small-Cell Lung
Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy
The primary objective of this study is to evaluate the tolerability and the maximum tolerated dose of Conformal or Intensity-Modulated Radiotherapy when given in combination with gefitinib 250mg in Chinese patients with IIIB or…
- Trial name
- NCT00497250
- Testing
- Gefitinib, Radiation Therapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Colorectal Cancer, Lung Cancer
AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Colorectal Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00107250
- Testing
- capecitabine, carboplatin, cediranib maleate
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- NCIC Clinical Trials Group
Non-small Cell Lung Cancer Metastatic
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
Title: Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study.
- Trial name
- VIVOS (NCT01848613)
- Testing
- Vinorelbine
- Where
- 8 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Stage 4 NSCLC, Radiotherapy
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
- Trial name
- DRO2301 (NCT06262321)
- Testing
- Prophylactic Palliative Radiotherapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Rochester
Non-small Cell Lung Cancer
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
Primary goal of the study is to assess the overall survival of the addition of hypofractionated image guided radiotherapy concurrently with Docetaxel and cisplatin.
- Trial name
- SMART (NCT00887315)
- Testing
- Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Chicago
Carcinoma, Non-Small-Cell Lung
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally…
- Trial name
- SAFFRON (NCT05261399)
- Testing
- Savolitinib, Osimertinib, Pemetrexed
- Where
- 214 sites in United States, Argentina and 25 more
- Volunteers
- 341 people
- Sponsor
- AstraZeneca
NSCLC Stage IIIB, NSCLC Stage IV
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with…
- Trial name
- NCT05281406
- Testing
- Osimertinib, Pemetrexed, Cisplatin
- Where
- 16 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Goethe University
Lung Cancer, Non-Small Cell Lung Cancer
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
The main purpose of this study is to find out if the drugs MEK162 and erlotinib (Tarceva) given in combination are safe and have beneficial effects in patients who have NSCLC. The U.S.
- Trial name
- NCT01859026
- Testing
- MEK162, Erlotinib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy
RATIONALE: Mistletoe may help the body build an immune response and may improve quality of life to help patients live more comfortably.
- Trial name
- NCT00052325
- Testing
- mistletoe extract
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Solid Tumor
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and…
- Trial name
- NCT07003321
- Testing
- HRS-4508 tablet
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
PFS
- Trial name
- NCT01860508
- Testing
- pemetrexed /carboplatin
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer Stage IV, Lung Cancer, Non-small Cell
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Immune-checkpoint inhibitors have recently become available as a new therapy for a variety of cancers. This drugs function by boosting the anti-cancer immune response, but unfortunately, may cause off-target, non-specific immune…
- Conditions
- Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
- Trial name
- NCT04595734
- Testing
- No intervention due to observational methods of study
- Where
- 3 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
NSCLC Stage IV, NSCLC, Stage III
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib.
- Trial name
- REPOROS (NCT06552234)
- Testing
- Repotrectinib
- Where
- 20 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
This phase II trial tests how well photoimmunotherapy (PIT) with ASP-1929 in combination with cemiplimab works in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC) that has not responded to previous…
- Conditions
- Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06943664
- Testing
- Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer
Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer
The majority of patients diagnosed with advanced NSCLC are treated with platinum-doublet chemotherapy regimens, except those harboring specific oncogenic drivers such as epidermal growth-factor-receptor (EGFR) mutations or…
- Trial name
- VinMetAtezo (NCT03801304)
- Testing
- Atezolizumab, Vinorelbine
- Where
- 13 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.